Ignite Creation Date:
2025-12-24 @ 5:13 PM
Ignite Modification Date:
2025-12-27 @ 9:30 AM
Study NCT ID:
NCT00215150
Status:
COMPLETED
Last Update Posted:
2014-10-31
First Post:
2005-09-20
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Geodon for the Treatment of Refractory Social Anxiety Disorder
Sponsor:
Duke University
Organization:
Study Overview
Official Title:
Ziprasidone for the Treatment of Refractory Social Anxiety Disorder
Status:
COMPLETED
Status Verified Date:
2013-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
SAD
Brief Summary:
The purpose of this study is to examine the effectiveness and tolerability of augmentation treatment of ziprasidone to achieve remission among patients with social anxiety disorder (SAD) who did not remit on sertraline treatment alone
Detailed Description:
This is a two-phase study consisting of 8 weeks of open label treatment with sertraline (50-200 mg/day) in patients with SAD and in those who fail to demonstrate symptom remission on sertraline alone, 8 weeks of randomized, double-blind, placebo-controlled augmentation with ziprasidone.
Study Oversight
Has Oversight DMC:
False
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 6479 | OTHER | Duke legacy protocol number | View |